Journal article
Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer
KYC Fung, I Priebe, L Purins, B Tabor, GV Brierley, T Lockett, E Nice, P Gibbs, J Tie, P McMurrick, J Moore, A Ruszkiewicz, A Burgess, LJ Cosgrove
Cancer Biomarkers | Published : 2013
DOI: 10.3233/CBM-130335
Abstract
BACKGROUND: Lipocalin 2 has been implicated in colorectal tumorigenesis but its usefulness as a diagnostic marker for the disease has previously never been determined. METHODS: We have used ELISA immunoassay to measure the level of serum lipocalin 2 in a cohort consisting of colorectal cancer patients (n=196) and age/gender matched controls (n=99). RESULTS: The median concentration of lipocalin 2 was found to be significantly higher (p< 0.0001) in the patient group (105.9 ng/mL, range 10.8-444.7 ng/mL) when compared to the control subjects (86.4 ng/mL, range 17.1-190.0 ng/mL). Additionally, no significant difference was observed between disease stage (Dukes' or T stage) in the patient cohort..
View full abstractGrants
Funding Acknowledgements
The authors would like to thank the Victorian Cancer Biobank (Melbourne, Victoria) for their assistance with sample collection. This work was funded by the CSIRO Preventative Health National Research Flagship.